Sort   by:  
 Page size 
TranscriptomicsPatient Derived Xenograft for Delivery of Precision Medicine in Castrate Resistant Prostate Cancer
Developing animal models representating the cancer biology of advanced prostate cancer patients is challenging but essential for delivering individualized medical therapies. In an effort to develop patient derived xenograft (PDX) models, we took the metastatic site tissue from the rib lesion twice (...
ORGANISM(S): Homo sapiens 
2015-06-30 | E-GEOD-70380 | biostudies-arrayexpress
GenomicsGlioma GWAS summary statistics
Meta-analysis association statistics from case-control analysis (includes imputed SNPs)
EGAD00010001657 | EGA
GenomicsSummary statistics from genome-wide association study in glioma of 12,488 cases and 18,169 controls.
Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,488 cases and 18,169 controls. We identified five ...
EGAS00001003372 | EGA
GenomicsGlioma GWAS summary statistics DAC
Data Access Committee EGAC00001001116
EGAC00001001116 | EGA
GenomicPROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease.

Understanding the molecular biology behind castration-resistant prosta...

phs001141 | dbGaP
Sort   by:  
 Page size